ArticleGynecologic oncology reports2017
Comprehensive genomic profiling (CGP) of ovarian clear cell carcinomas (OCCC) identifies clinically relevant genomic alterations (CRGA) and targeted therapy options.
Article in Gynecologic oncology reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 26 citations in OpenAlex.
- From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer.Journal of ovarian research · 2024Review
- Genomic profiling of ovarian clear cell carcinoma in Chinese patients reveals potential prognostic biomarkers for survival.Annals of medicine · 2023Article
- Pathologic complete response to immune checkpoint inhibitor in a stage IIIB ovarian clear cell carcinoma patient withGland surgery · 2022Article
- Genomic alterations in gynecological malignancies: histotype-associated driver mutations, molecular subtyping schemes, and tumorigenic mechanisms.Journal of human genetics · 2021Review
- Genetic alterations and their therapeutic implications in epithelial ovarian cancer.BMC cancer · 2021Article
- p53 and ANXA4/NF‑κB p50 complexes regulate cell proliferation, apoptosis and tumor progression in ovarian clear cell carcinoma.International journal of molecular medicine · 2020Article
- Human papillomavirus 16 promotes microhomology-mediated end-joining.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Advancing Drug Development in Gynecologic Malignancies.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Review
- Resibufogenin inhibits ovarian clear cell carcinoma (OCCC) growthAmerican journal of translational research · 2019Article
- Candidate synthetic lethality partners to PARP inhibitors in the treatment of ovarian clear cell cancer.Biomedical reports · 2017Article
- Involvement of Chromatin Remodeling Genes and the Rho GTPasesFrontiers in oncology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
•MTOR pathway genes are often mutated in ovarian clear cell carcinomas (OCCC).•11.2% of OCCC have targetable alterations only in the mTOR pathway.•MTOR pathway mutations in OCCC can underlie robust, lasting responses to everolimus.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.